Sponsor

GE Healthcare Limited

United Kingdom Pollards Wood, Nightingales Lane, HP8 4SP, United Kingdom

About the sponsor

Research activity includes positron emission tomography and computed tomography applications in metastatic breast cancer, colorectal cancer, gastric cancer, ovarian cancer, pancreatic cancer, and head and neck squamous cell carcinoma. The portfolio also covers imaging of peritoneal carcinomatosis and other advanced solid tumours.

FES PET/CT
HER2 imaging
68Ga PET/CT
Peritoneal carcinomatosis detection

Clinical interest extends to imaging biomarkers that support treatment selection and disease characterisation in advanced cancer.

About Specializations

GE Healthcare Limited runs clinical trials in conditions such as Gastric cancer, Colorectal cancer, Pancreatic carcinoma, Hepatic lesion, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

4 clinical trials

Gastric cancer+2

Recruiting

InvestigationalNo placebo

A study to evaluate the use of FAPI-46 (68Ga) imaging to detect peritoneal cancer spread in patients with colorectal, gastric, ovarian, or pancreatic cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
Sponsor:GE Healthcare Limited